Home › Funds › Lingotto Investment Management LLP › RXRX

Lingotto Investment Management LLP position in RXRX

RECURSION PHARMACEUTICALCLASS A · Health Care

Lingotto Investment Management LLP reported holding 2,206,661 shares of RXRX (RECURSION PHARMACEUTICALCLASS A) in its Q2 2026 13F filing — a position valued at US$8.1M, representing 0.19% of its reported portfolio and ranking #26 among its reported holdings. Lingotto Investment Management LLP has disclosed RXRX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)2.21M sh
Reported value held$8.10M
Portfolio Weight0.19%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Lingotto Investment Management LLP's RXRX position evolved

Lingotto Investment Management LLP first disclosed a stake in RXRX in Q3 2023 at 775,077 shares (US$5.9M). The position peaked in Q2 2024 at 3,675,077 shares, worth US$27.6M. Across 12 filings, Lingotto Investment Management LLP increased the stake 5 time(s), trimmed it 1 time(s) and left it unchanged 5 time(s). The most recent filing (Q2 2026) shows 2,206,661 shares valued at US$8.1M — a reduction of -3,675,077 shares quarter over quarter.. Notable position changes include a 142% increase in Q4 2023 (shares rose 1% over the following quarter), a 69% increase in Q2 2024 (shares fell 12% over the following quarter), a 62% trim in Q2 2026 (shares rose 13% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 775.08K $5.93M New
Q4 2023 1.88M $18.49M Add
Q1 2024 2.18M $21.69M Add
Q2 2024 3.68M $27.56M Add
Q3 2024 3.68M $24.22M Hold
Q4 2024 3.68M $24.84M Hold
Q1 2025 3.68M $19.44M Hold
Q2 2025 3.68M $18.60M Hold
Q3 2025 3.68M $17.93M Hold
Q4 2025 4.93M $20.17M Add
Q1 2026 5.88M $18.06M Add
Q2 2026 2.21M $8.10M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RXRX and 13F data

RXRX (RECURSION PHARMACEUTICALCLASS A) is a Health Care company. 29 other funds we track also report a position in RXRX — the largest reported positions include ARK Invest (US$151.7M), SOFTBANK GROUP CORP. (US$50.0M), MIC Capital Management UK LLP (US$35.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RXRX

All RXRX fund holders →

FAQ

How long has Lingotto Investment Management LLP held RXRX?

Lingotto Investment Management LLP has disclosed RXRX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Lingotto Investment Management LLP's current position in RXRX?

As of Q2 2026, Lingotto Investment Management LLP holds 2.21M shares of RXRX (RECURSION PHARMACEUTICALCLASS A), valued at $8.10M, representing 0.19% of its reported portfolio and ranking #26.

Has Lingotto Investment Management LLP been buying or selling RXRX?

In the latest 13F filing (Q2 2026), Lingotto Investment Management LLP reduced its position in RXRX. The position peaked in Q2 2024 at 3.68M shares.

Which other funds hold RXRX?

Other major institutional holders of RXRX include ARK Invest, SOFTBANK GROUP CORP., MIC Capital Management UK LLP, among 29 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.